BCR-ABL1 tyrosine kinase inhibitor-associated thyroid dysfunction: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature.
Am J Hematol
; 95(12): E332-E335, 2020 12.
Article
in En
| MEDLINE
| ID: mdl-32918288
Full text:
1
Database:
MEDLINE
Main subject:
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Fusion Proteins, bcr-abl
/
Protein Kinase Inhibitors
/
Hyperthyroidism
/
Hypothyroidism
Type of study:
Risk_factors_studies
Limits:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Child
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Am J Hematol
Year:
2020
Type:
Article